Alvogen’s subsidiary in Taiwan, Lotus Pharmaceuticals has announced its plans to make significant investment in the development and manufacturing of oncology pharmaceuticals at its facility in Nantou, Taiwan. The investment program is designed to further enhance customer service and supply of high-quality pharmaceuticals for Lotus’ markets around the world.
Robert Wessman, Lotus Chairman of the Board said: “At Lotus we are inspired to help patients around the world by increasing the accessibility of high-quality oncology pharmaceuticals. With additional investment into the Nantou facility, we are taking a significant step toward becoming a major player in the oncology industry. In recent weeks and months, we have reached some very important business milestones, including the successful first-to-market launch of Lenalidomide and multiple strategic partnership agreements in Europe and the U.S.”
Petar Vazharov, General Manager of Lotus said: “The long-term investment plan aims to improve our ability to handle R&D, supply chain and operation complexity as a result of growing export demand of oral oncology and special dosage products. Nantou has been a great home to Lotus and we are excited to reinforce our commitment to the vibrant community with our upgraded facility.”
Lotus’ Nantou site has been audited by Taiwanese, U.S., EU and Japanese regulatory authorities, enabling the facility to manufacture products for nearly every market in the world. In addition to standard solid oral dose manufacturing, Lotus has very unique capabilities around the production of hormonal products, soft gelatin capsules, cytotoxic and high potency molecules.
The Lotus management team graciously acknowledged government officials from TFDA, Nantou County Government, Central Taiwan Science Park, and NanGang Industrial Park for their invaluable roles in advancing the project.